Checkpoint ends trial due to Russian invasion; Terns lines up more cash for NASH
You can count a Phase III program at Checkpoint Therapeutics as the latest collateral damage from Russia’s invasion of Ukraine.
The biotech $CKPT
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
